To appear in Best of the Brokers, email your research to firstname.lastname@example.org
Numis moved the research company from a “buy” rating to an “add” rating, ahead of its results for the six months to January. The broker said it expects continued growth from the firm’s BrandIndex and Omnibus brands, and also expects revenue predictability and margin profile to improve.
Jefferies downgraded its rating on the pharmaceuticals firm from “buy” to “hold”, following disappointing guidance and more muted uptake of its gout treatment, Mitigare. The broker said the new rating is appropriate “until there is greater visibility on catalysts and mid-term prospects”.
Whitman Howard reiterated its “hold” rating on the water company, ahead of its capital markets day which “should provide encouraging updates on all fronts”. The broker said that as water firms have been relatively weak in recent months, Severn is “beginning to look reasonably good value”.